Schrödinger reported robust double-digit revenue growth for Q4 2025 as its business model transitions from primarily licensing its computational platform to forging revenue-sharing drug discovery partnerships. Management highlighted progress in expanding its software platform services, signing new collaborations with biopharma firms, and deploying its physics-based modeling tools across multiple partnered programs.